Based on the BB Biotech AG stock forecast from 0 analysts, the average analyst target price for BB Biotech AG is not available over the next 12 months. BB Biotech AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BB Biotech AG is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, BB Biotech AG’s stock price was CHF 35.40. BB Biotech AG’s stock price has changed by -2.07% over the past week, -1.53% over the past month and -12.48% over the last year.
No recent analyst target price found for BB Biotech AG
No recent average analyst rating found for BB Biotech AG
Company Overview BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland. Address: Seestrasse 16, Küsnacht, Switzerland, CH-8700 Read Less
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fun...Read More
Frequently Asked Questions About BB Biotech AG (BION:SW) Stock
Stock Target Advisor's fundamental analysis for BB Biotech AG's stock is Slightly Bullish .
BION:SW stock's dividend yield is 5.38%.
Our analysis grades BION:SW stock's dividend yield at A+. This means that BION:SW stock's dividend yield is above 100% of the stocks in the Biotechnology sector in the SW exchange.
Based on this BION:SW may be a good dividend stock for its sector.
Unfortunately we do not have enough data on BION:SW's stock to indicate what its average analyst target is.
BION:SW stock's Price/Earning ratio is 16.18.
Our analysis grades BION:SW stock's Price / Earning ratio at F. This means that BION:SW stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Biotechnology sector in the SW exchange.
Based on this BION:SW may be a overvalued for its sector.
The last closing price of BION:SW's stock was CHF 35.40.
The most recent market capitalization for BION:SW is CHF 2.03B.
Unfortunately we do not have enough analyst data on BION:SW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BB Biotech AG's stock.
As per our most recent records BB Biotech AG has 10 Employees.
BB Biotech AG's registered address is Seestrasse 16, Kusnacht, Switzerland, 8700.
You can get more information about it from BB Biotech AG's website at https://www.bbbiotech.ch/en/bb-biotech/.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About BB Biotech AG (BION:SW) Stock
Stock Target Advisor's fundamental analysis for BB Biotech AG's stock is Slightly Bullish .
BION:SW stock's dividend yield is 5.38%.
Our analysis grades BION:SW stock's dividend yield at A+. This means that BION:SW stock's dividend yield is above 100% of the stocks in the Biotechnology sector in the SW exchange.
Based on this BION:SW may be a good dividend stock for its sector.
Unfortunately we do not have enough data on BION:SW's stock to indicate what its average analyst target is.
BION:SW stock's Price/Earning ratio is 16.18.
Our analysis grades BION:SW stock's Price / Earning ratio at F. This means that BION:SW stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Biotechnology sector in the SW exchange.
Based on this BION:SW may be a overvalued for its sector.
The last closing price of BION:SW's stock was CHF 35.40.
The most recent market capitalization for BION:SW is CHF 2.03B.
Unfortunately we do not have enough analyst data on BION:SW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BB Biotech AG's stock.
As per our most recent records BB Biotech AG has 10 Employees.
BB Biotech AG's registered address is Seestrasse 16, Kusnacht, Switzerland, 8700.
You can get more information about it from BB Biotech AG's website at https://www.bbbiotech.ch/en/bb-biotech/.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BION:SW !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
